Mechanism of Invasion of Malignant Tumors (Ramdas Nayak / Robbins Pathology)

Note: Ramdas Nayak's Essentials of Pathology is not directly available in the library, but its content on tumor invasion is drawn from the same authoritative framework as Robbins & Cotran. The explanation below follows that framework in detail.

Contrast: Benign vs. Malignant Growth

Mechanism of Invasion of the Extracellular Matrix (ECM)

1. Breach the underlying basement membrane
2. Traverse the interstitial connective tissue
3. Penetrate the vascular basement membrane (for hematogenous spread)

Step 1 - Loosening of Tumor Cell-to-Tumor Cell Interactions (Detachment)

• Normal epithelial cells are tightly held together by E-cadherins - transmembrane glycoproteins that mediate homotypic adhesion and relay intercellular signals.
• In malignant tumors, E-cadherin function is lost due to:
  • Mutations in the E-cadherin gene (CDH1) - seen in gastric and breast adenocarcinomas
  • Transcriptional silencing through Epithelial-Mesenchymal Transition (EMT)
• EMT is a key process controlled by the transcription factors SNAIL and TWIST, which:
  • Downregulate epithelial markers (E-cadherin)
  • Upregulate mesenchymal markers (vimentin, smooth muscle actin)
  • Produce a pro-migratory phenotype that facilitates invasion and metastasis
• Loss of E-cadherin removes the "glue" that holds cells together, enabling individual tumor cells to detach and become mobile.

Step 2 - Degradation of ECM (Enzymatic Destruction of Basement Membrane and Connective Tissue)

• Tumor cells degrade the ECM by secreting proteolytic enzymes or by inducing stromal cells (fibroblasts, macrophages) to do so.
• Key enzymes involved:
  • Matrix metalloproteinases (MMPs) - the most important group. Particularly MMP-9 (gelatinase), which cleaves type IV collagen found in the epithelial and vascular basement membrane. MMP-9 also:
    • Releases VEGF from ECM-sequestered pools (promoting angiogenesis)
    • Generates collagen and proteoglycan cleavage products with chemotactic, angiogenic, and growth-promoting effects
  • Cathepsin D - a lysosomal protease
  • Urokinase plasminogen activator (uPA) - activates plasmin, which further degrades ECM
• Benign tumors (breast, colon, stomach) show little MMP-9 activity, while malignant counterparts overexpress it.
• Simultaneously, the concentrations of metalloproteinase inhibitors (TIMPs) are reduced in many cancers, tilting the balance further toward degradation.

Step 3 - Altered Cell Attachment to ECM (Changes in Integrin Expression)

• Integrins are transmembrane proteins that mediate cell-to-cell and cell-to-ECM adhesion.
• In normal epithelial cells, integrins that bind basement membrane laminin and collagens are restricted to the basal aspect - maintaining a resting, polarized state.
• Loss of adhesion in normal cells triggers anoikis (apoptosis induced by detachment).
• In tumor cells, however:
  • The profile of integrins expressed is altered
  • There is a shift toward integrins that bind degraded ECM components (fibronectin fragments, osteopontin, etc.) and provide traction for migration
  • Tumor cells are able to migrate along cleavage sites created by MMP-mediated ECM destruction
  • Tumor cells become resistant to anoikis, allowing survival after detachment

Step 4 - Migration and Invasion of Tumor Cells

• This is the final active phase in which tumor cells use the degraded ECM as a scaffold to migrate through tissues.
• Migration is driven by:
  • Chemotactic factors - produced by inflammatory cells (macrophages) and stromal cells (fibroblasts). These include:
    • Autocrine motility factors secreted by tumor cells themselves
    • Cleavage products of ECM components (e.g., collagen fragments) acting as chemoattractants
    • Growth factors such as IGF-I and IGF-II that stimulate cell locomotion
  • Assembly of actin filaments at the leading edge of the cell - providing the cytoskeletal force for locomotion
  • Tumor cells bind to newly exposed cleavage sites in the ECM and use them as "traction points" for forward movement

The Full Metastatic Cascade (Overview)

1. Clonal expansion and angiogenesis in primary tumor
2. Development of a metastatic subclone with additional mutations
3. Adhesion to and invasion of basement membrane (as above)
4. Passage through the ECM
5. Intravasation - entry into blood vessels or lymphatics
6. Interaction with host lymphoid cells; formation of tumor cell embolus (with platelets)
7. Adhesion to vascular basement membrane at distant site
8. Extravasation into the distant tissue
9. Formation of metastatic deposit with new angiogenesis and growth

Key Molecular Players - Summary Table

Why Metastasis is Inefficient

• Overcoming immune defenses at every step
• Adapting to a completely different microenvironment at the distant site (e.g., bone marrow, brain, liver)
• Individual "metastasis genes" have not been identified because the metastatic phenotype likely requires the accumulation of multiple complementary genetic and epigenetic alterations